China-based EOC Pharma Group has announced a strategic partnership with compatriot firm China National Accord Medicines Corporation Ltd, granting the latter distribution and importing rights to its Vascepa (ethyl Icosapentate) and Mulpleta (lusutrombopag). The collaboration aims to enhance the commercialization of both products within the Chinese market.
Vascepa: A FDA-Approved Treatment for High-Risk Cardiovascular Patients
Vascepa, originally developed by Amarin, was approved in the US in 2013 to lower triglyceride levels in adult patients with severe hypertriglyceridemia (≥ 500 mg/dL). EOC secured a licensing deal with Amarin in 2015, obtaining development and commercialization rights for the drug in Greater China. Currently, Vascepa is the first and only FDA-approved treatment for high-risk patients with persistent cardiovascular risk after statin therapy. The drug gained access to Boao Lecheng in January 2021 and received marketing approval in Hong Kong in March 2022 for use in combination treatment to reduce the risk of hospitalization caused by various cardiovascular events and in adult patients with elevated triglyceride (TG) levels (≥ 150 mg/dL) combined with diagnosed cardiovascular disease or diabetes with additional risk factors.
Mulpleta: An Effective Treatment for Severe Thrombocytopenia
Lusutrombopag is an oral small molecule human thrombopoietin receptor agonist (TPO-RA) that stimulates the production of endogenous platelets, offering a well-tolerated and more effective treatment option for patients with severe thrombocytopenia requiring invasive surgery. EOC obtained exclusive rights to the drug from Japan-based Shionogi through a 2019 licensing deal.-Fineline Info & Tech
